Proteasome dysfunction in aged human α-synuclein transgenic mice

Abstract A deficit in proteasome function in Parkinson's disease has been speculated. We characterized the ubiquitin–proteasome system in three regions of brain from transgenic and nontransgenic littermates. Mice expressing a doubly mutated form of human α-synuclein had significant impairments whereas mice expressing the wild-type gene had lesser changes compared to nontransgenic littermates. Significant abnormalities in line hm2α-SYN-39 included declines in 20S-mediated proteolytic activity, the level of the 19S proteasome subunits Rpt1 and Rpn2, and the level of soluble total high MW ubiquitin cross-reacting proteins. Line hwα-SYN-5 had significant, but restricted proteasome abnormalities. The severity of impairment was proportional to the substantia nigra dopaminergic neuronal loss previously identified. There were significant correlations between the level of Rpn2 with the level of Rpt1, the activity of the 20S proteasome, and the level of soluble high MW ubiquitin cross-reacting proteins. These abnormalities in symptomatic line hm2α-SYN-39 mice are consistent with abnormalities identified in tissue from patients with Parkinson's disease.

[1]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[2]  H. Braak,et al.  Alpha-synuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson’s disease are detectable by an advanced silver-staining technique , 1999, Acta Neuropathologica.

[3]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[4]  C. Olanow,et al.  Ubiquitin–proteasome system and Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[5]  K. Davies.  Degradation of oxidized proteins by the 20S proteasome. , 2001, Biochimie.

[6]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[7]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[8]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Iwatsubo,et al.  Ubiquitination of α-Synuclein† , 2005 .

[10]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[11]  J. Agar,et al.  Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis , 2004, Journal of neurochemistry.

[12]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[13]  C. Olanow,et al.  Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures , 2002, Journal of neurochemistry.

[14]  Yi Zhao,et al.  Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability , 2003, Neuroscience Letters.

[15]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[16]  C. Olanow,et al.  Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease , 2003, Annals of neurology.

[17]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[18]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[19]  Eric K. Richfield,et al.  Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice , 2004 .

[20]  Bertrand Friguet,et al.  Impairment of proteasome structure and function in aging. , 2002, The international journal of biochemistry & cell biology.

[21]  L. Petrucelli,et al.  Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system , 2004, Annals of medicine.

[22]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[23]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[24]  C. Olanow,et al.  Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.

[25]  S. Johnston,et al.  Subcellular Localization, Stoichiometry, and Protein Levels of 26 S Proteasome Subunits in Yeast* , 1999, The Journal of Biological Chemistry.

[26]  T. Sherer,et al.  Ubiquitin–proteasome system and Parkinson's diseases , 2005, Experimental Neurology.

[27]  R. Krüger,et al.  Polymorphisms of the α-synuclein promoter: expression analyses and association studies in Parkinson's disease , 2003, Journal of Neural Transmission.

[28]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[29]  H. Braak,et al.  Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry , 1999, Neuroscience Letters.

[30]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[31]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[32]  K. Tanaka,et al.  Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. , 2000, The Biochemical journal.

[33]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[34]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[35]  J. Hothersall,et al.  The Functional Significance of the Pentose Phosphate Pathway in Synaptosomes: Protection Against Peroxidative Damage by Catecholamines and Oxidants , 1982, Journal of neurochemistry.

[36]  W. Markesbery,et al.  Decreased levels of proteasome activity and proteasome expression in aging spinal cord , 2000, Neuroscience.

[37]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[38]  B. Friguet,et al.  Age-related alterations of proteasome structure and function in aging epidermis , 2000, Experimental Gerontology.

[39]  C. Ross,et al.  Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.